– USA, MD – BeiGene (NASDAQ: BGNE | HKEX: 06160 | SSE: 688235), a global, science-driven biotechnology company today announced the appointment of Dr. Margaret Dugan, (M.D.) and Dr. Alessandro Riva (M.D.), to its Board of Directors.
Dr. Dugan will also join the scientific advisory committee while Dr. Riva will join the nominating and corporate governance and scientific advisory committees.
“Drs. Dugan and Riva both bring significant oncology expertise to BeiGene’s Board of Directors during a key period of Company growth as we advance our high-value, late-stage portfolio,. They bring complementary medical and commercial experience at both nimble biotechs and global pharmaceutical organizations that will support our efforts to become a leader and transformational agent in the industry,” said Co-Founder, CEO and Chairman, John Oyler.
Concurrently, Sam Su will be stepping down from the board of directors.
“Dr. Dugan is widely recognized for her oncology expertise and commitment to bringing important medical breakthroughs to patients around the world, We are very pleased to welcome her to our Board of Directors, and her expertise will be highly valuable as we work to expand our pipeline and make an impact for the greater good of patients,” said Mr. Oyler.
He added: “Dr. Riva brings key industry insights and depth of experience to our board, having a steadfast commitment to the patients we work to help and the values with which we do so. Our team welcomes Dr. Riva to our Board of Directors, and we look forward to incorporating his insights as we deliver on our important mission.”
About Dr. Margaret Dugan
Dr. Margaret Dugan is currently CMO at Dracen Pharmaceuticals, a privately held pharmaceutical company based in New York that leverages immuno-metabolism in oncology. She joined Dracen in 2018 with more than 20 years of experience in oncology and previously held senior leadership roles at Novartis Oncology, including Senior Vice President and Global Program Head, developing innovative medicines for patients. Dr. Dugan also held several development positions at Schering-Plough (now Merck & Co.) and American Cyanamid.
Dr. Dugan received her B.A. and medical degrees and training in hematology and oncology from New York University.
“I am honored to join BeiGene’s board and am excited to work alongside this talented and dedicated team to bring high-quality, innovative therapies to more people around the world who need them. I am impressed by BeiGene’s broad internal research and development capabilities as well as its in-licensed portfolio of exciting new assets, and the team’s values of putting patients first, having bold ingenuity along with a collaborative spirit and driving excellence to make a lasting impact in the world,” said Dr. Dugan.
About Dr. Alessandro Riva
Dr. Alessandro Riva is currently CEO of Intima Bioscience, a privately-held clinical-stage gene, and cell therapy company. Before joining Intima, he served as CEO at privately held Ichnos Sciences, where he built a biotechnology company focused on bi- and tri-specific antibodies in oncology and biologics in autoimmune diseases. Before Ichnos, he was EVP and Global Head of Oncology Therapeutics and Cell & Gene Therapy at Gilead Sciences, where he was instrumental in the acquisition of Kite Pharma. Before Gilead, Dr. Riva was EVP and Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals, where he contributed significantly to the Oncology Business Unit and the Cell and Gene Therapy Unit. He was also interim president of Novartis Oncology during the acquisition of GSK Oncology. Dr. Riva is currently on the Board of Directors of Century Therapeutics, a NASDAQ-listed biotechnology company developing innovative iPSC-derived NK and T cell therapies. He previously held roles at Farmitalia Carlo Erba, Rhône-Poulenc Rorer, and Aventis and co-founded the Breast Cancer International Research Group and the Cancer International Research Group, where he served as CEO.
He received his M.D. in medicine and surgery from the University of Milan and a certificate board in oncology and hematology from the same institution.
Dr. Riva said, “BeiGene is building next-generation global biotech with unique capabilities within our industry. I am honored to join the Board and look forward to joining at such an exciting time, with key catalysts in the near-term, building on the long-term strategy of this fantastic organization.”
About BeiGene
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting the development of our diverse pipeline of novel therapeutics through our capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents.
For more information: https://www.beigene.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.